<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956382</url>
  </required_header>
  <id_info>
    <org_study_id>2016-0014</org_study_id>
    <nct_id>NCT02956382</nct_id>
  </id_info>
  <brief_title>Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma</brief_title>
  <official_title>Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hackensack Meridian Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II study in which patients will be enrolled in a standard 3+3 design. Once&#xD;
      the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory&#xD;
      grade 1-3a follicular lymphoma, there will be a 17-patient phase II study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In vitro studies of ibrutinib and venetoclax have noted significant cytotoxicity and synergy&#xD;
      in mantle cell lymphoma and chronic lymphocytic leukemia cell lines.Data have demonstrated&#xD;
      synergy between the two agents in various other B-cell Non-Hodgkin Lymphoma (NHL) cell lines.&#xD;
      The investigators theorize that the combination of ibrutinib and venetoclax will provide&#xD;
      dual, yet unique, targeted inhibition for patients with follicular lymphoma, resulting in&#xD;
      both significant efficacy and less nonspecific toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Phase 2 dose</measure>
    <time_frame>18 months</time_frame>
    <description>The maximum tolerated dose of Ibrutinib and Venetoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>36 months</time_frame>
    <description>Response rate seen in the combination versus 30% response rate for current individual therapies for this group of patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Ibrutinib</measure>
    <time_frame>18 months</time_frame>
    <description>Steady-state plasma concentrations of ibrutinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Venetoclax</measure>
    <time_frame>18 months</time_frame>
    <description>Steady-state plasma concentrations of venetoclax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>36 months</time_frame>
    <description>Toxicity (attribute and grade) will be summarized for each dose level for all patients who receive at least one dose of study treatment</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Refractory Follicular Lymphoma</condition>
  <condition>Relapsed Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Phase I - Dose Level 0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib (capsule) - 420mg Venetoclax (tablet) - 400mg&#xD;
Each medication is taken daily. Treatment cycles are 28 days long.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I - Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 400mg&#xD;
Each medication is taken daily. Treatment cycles are 28 days long.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I - Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 600mg&#xD;
Each medication is taken daily. Treatment cycles are 28 days long.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I - Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 800mg&#xD;
Each medication is taken daily. Treatment cycles are 28 days long.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Phase II dose will be the maximum tolerated dose as determined in the Phase I portion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Ibrutinib is dispensed as a capsule.</description>
    <arm_group_label>Phase I - Dose Level 0</arm_group_label>
    <arm_group_label>Phase I - Dose Level 1</arm_group_label>
    <arm_group_label>Phase I - Dose Level 2</arm_group_label>
    <arm_group_label>Phase I - Dose Level 3</arm_group_label>
    <arm_group_label>Phase II Dose</arm_group_label>
    <other_name>PCI-32765</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Venetoclax is dispensed as a tablet.</description>
    <arm_group_label>Phase I - Dose Level 0</arm_group_label>
    <arm_group_label>Phase I - Dose Level 1</arm_group_label>
    <arm_group_label>Phase I - Dose Level 2</arm_group_label>
    <arm_group_label>Phase I - Dose Level 3</arm_group_label>
    <arm_group_label>Phase II Dose</arm_group_label>
    <other_name>ABT-199</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Relapsed or refractory, histologically confirmed follicular lymphoma, grade I, II, or&#xD;
             IIIa which requires therapy defined by at least one of the following:&#xD;
&#xD;
               -  Constitutional symptoms&#xD;
&#xD;
               -  Cytopenias&#xD;
&#xD;
          2. High tumor burden (single mass &gt; 7 cm, three masses &gt; 3 cm, symptomatic splenomegaly,&#xD;
             organ compression or compromise, ascites, pleural effusion)Must have received at least&#xD;
             two prior systemic therapies&#xD;
&#xD;
          3. All risk by FLIPI 0-5 factors (Appendix I)&#xD;
&#xD;
          4. Measurable disease Measurable disease must be present either on physical examination&#xD;
             or imaging studies; non-measurable disease alone is not acceptable. Any tumor mass &gt;&#xD;
             1.5 cm is acceptable.&#xD;
&#xD;
             Lesions that are considered non-measurable include the following:&#xD;
&#xD;
               -  Bone lesions (lesions if present should be noted)&#xD;
&#xD;
               -  Ascites&#xD;
&#xD;
               -  Pleural/pericardial effusion&#xD;
&#xD;
               -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
               -  Bone marrow (involvement by lymphoma should be noted)&#xD;
&#xD;
          5. Adequate hematologic function independent of transfusion and growth factor support for&#xD;
             at least 3 weeks prior to screening unless attributable to disease. Defined as:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt;1000 cells/mm3 (1.0 x 109/L). ANC &gt; 500&#xD;
                  cells/mm3 is permissible if due to disease.&#xD;
&#xD;
               -  Platelet count &gt;50,000 cells/mm3 (50 x 109/L) unless attributable to disease.&#xD;
                  Platelet count &gt; 20,000 cells/mm3 is permissible if due to disease.&#xD;
&#xD;
               -  Hemoglobin &gt;8.0 g/dL.&#xD;
&#xD;
          6. Adequate hepatic and renal function defined as:&#xD;
&#xD;
               -  Serum aspartate transaminase (AST) or alanine transaminase (ALT) ≤ 2.5 x upper&#xD;
                  limit of normal (ULN) Serum aspartate transaminase (AST) or alanine transaminase&#xD;
                  (ALT) ≤ 5 is permissible if due to disease.&#xD;
&#xD;
               -  Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of&#xD;
                  non-hepatic origin) Bilirubin ≤3 x ULN is permissible if due to disease.&#xD;
&#xD;
               -  Estimated Creatinine Clearance ≥50 ml/min (Cockcroft-Gault based on actual&#xD;
                  weight)&#xD;
&#xD;
          7. Prothrombin time (PT)/International normalized ratio (INR) &lt;1.5 x ULN and PTT (aPTT)&#xD;
             &lt;1.5 x ULN.&#xD;
&#xD;
          8. Men and women ≥ 18 years of age.&#xD;
&#xD;
          9. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. (Appendix II)&#xD;
&#xD;
         10. Female subjects who are of non-reproductive potential (i.e., post-menopausal by&#xD;
             history - no menses for ≥1 year; OR history of hysterectomy; OR history of bilateral&#xD;
             tubal ligation; OR history of bilateral oophorectomy). Female subjects of childbearing&#xD;
             potential must have a negative serum pregnancy test upon study entry.&#xD;
&#xD;
         11. Male and female subjects who agree to use highly effective methods of birth control&#xD;
             (e.g., condoms, implants, injectables, combined oral contraceptives, some intrauterine&#xD;
             devices (IUDs), sexual abstinence, or sterilized partner) during the period of therapy&#xD;
             and for 30 days after the last dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chemotherapy, monoclonal antibody, or small molecule kinase inhibitor less than or&#xD;
             equal 21 days prior to first administration of study treatment&#xD;
&#xD;
          2. Prior exposure to a Bruton's tyrosine kinase (BTK) or B-cell lymphoma 2 (BCL-2)&#xD;
             inhibitor.&#xD;
&#xD;
          3. History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to ibrutinib or venetoclax.&#xD;
&#xD;
          4. Known allergy to xanthine oxidase inhibitors and/or rasburicase for subjects at risk&#xD;
             for tumor lysis syndrome.&#xD;
&#xD;
          5. History of other malignancies, except:&#xD;
&#xD;
               -  Malignancy treated with curative intent and with no known active disease present&#xD;
                  for ≥ 3 years before the first dose of study drug and felt to be at low risk for&#xD;
                  recurrence by treating physician.&#xD;
&#xD;
               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease.&#xD;
&#xD;
               -  Adequately treated carcinoma in situ without evidence of disease.&#xD;
&#xD;
          6. Concurrent systemic immunosuppressant therapy (e.g., cyclosporine A, tacrolimus, etc.,&#xD;
             or chronic administration [&gt;14 days] of &gt; 20 mg/day of prednisone) within 28 days of&#xD;
             the first dose of study drug.&#xD;
&#xD;
          7. Undergone an allogeneic stem cell transplant within the past 1 year.&#xD;
&#xD;
          8. Current or history of graft versus host disease&#xD;
&#xD;
          9. Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.&#xD;
&#xD;
         10. Recent infection requiring systemic treatment that was completed ≤14 days before the&#xD;
             first dose of study drug.&#xD;
&#xD;
         11. Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved&#xD;
             to Common Terminology Criteria for Adverse Event (CTCAE, version 4.03), grade ≤1, or&#xD;
             to the levels dictated in the inclusion/exclusion criteria with the exception of&#xD;
             alopecia.&#xD;
&#xD;
         12. Known bleeding disorders (e.g., von Willebrand's disease) or hemophilia.&#xD;
&#xD;
         13. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.&#xD;
&#xD;
         14. Known HIV infection&#xD;
&#xD;
         15. Active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).&#xD;
&#xD;
             • Subjects who are positive for hepatitis B core antibody, hepatitis B surface&#xD;
             antigen, hepatitis C antibody, must have a negative polymerase chain reaction (PCR)&#xD;
             result for the respective disease before enrollment. Those who are PCR positive will&#xD;
             be excluded.&#xD;
&#xD;
         16. Any uncontrolled active systemic infection.&#xD;
&#xD;
         17. Major surgery within 4 weeks of first dose of study drug.&#xD;
&#xD;
         18. Any life-threatening illness, medical condition, or organ system dysfunction that, in&#xD;
             the investigator's opinion, could compromise the subject's safety or put the study&#xD;
             outcomes at undue risk.&#xD;
&#xD;
         19. Currently active, clinically significant cardiovascular disease, such as uncontrolled&#xD;
             arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart&#xD;
             Association Functional Classification; or a history of myocardial infarction, unstable&#xD;
             angina, or acute coronary syndrome within 6 months prior to randomization.&#xD;
&#xD;
         20. Unable to swallow capsules or tablets or malabsorption syndrome, disease significantly&#xD;
             affecting gastrointestinal function, or resection of the stomach or small bowel,&#xD;
             symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete&#xD;
             bowel obstruction.&#xD;
&#xD;
         21. Concomitant use of warfarin or other Vitamin K antagonists.&#xD;
&#xD;
         22. Requires treatment with a strong cytochrome P450 CYP3A4/5 inhibitor. (Appendix V)&#xD;
&#xD;
         23. Richter's transformation confirmed by biopsy.&#xD;
&#xD;
         24. Malabsorption syndrome or other condition precluding enteral route of administration.&#xD;
&#xD;
         25. Known Central nervous system (CNS) involvement by lymphoma&#xD;
&#xD;
         26. Erythema multiforme, toxic epidermal necrolysis, or Stevens-Johnson syndrome&#xD;
&#xD;
         27. Lactating or pregnant.&#xD;
&#xD;
         28. Unwilling or unable to participate in all required study evaluations and procedures.&#xD;
&#xD;
         29. Unable to understand the purpose and risks of the study and to provide a signed and&#xD;
             dated informed consent form (ICF) and authorization to use protected health&#xD;
             information (in accordance with national and local subject privacy regulations).&#xD;
&#xD;
         30. Currently active, clinically significant hepatic impairment (greater than or equal&#xD;
             moderate hepatic impairment according to the Child Pugh classification (see Appendix&#xD;
             IX)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chaitra Ujjani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Seattle Cancer Care Alliance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melin Vranesic</last_name>
      <phone>202-687-6653</phone>
      <email>mv764@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Catherine Lai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Kdiry, BSN</last_name>
      <phone>551-996-5952</phone>
      <email>Sabrina.Kdiry@HackensackMeridian.org</email>
    </contact>
    <contact_backup>
      <last_name>BSN</last_name>
    </contact_backup>
    <investigator>
      <last_name>Lori Ann Leslie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Grainger</last_name>
      <phone>206-606-1774</phone>
      <email>cmg95@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Chaitra Ujjani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2016</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ibrutinib</keyword>
  <keyword>Venetoclax</keyword>
  <keyword>Follicular</keyword>
  <keyword>Refractory</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

